Cargando…

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

Influenza vaccine production has traditionally relied on the use of embryonated chicken eggs for virus isolation and propagation, but recently, cell-culture-derived manufacturing methods have been introduced. During influenza vaccine production, by either conventional or cell culture methods, there...

Descripción completa

Detalles Bibliográficos
Autor principal: Gregersen, Jens-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115387/
https://www.ncbi.nlm.nih.gov/pubmed/18468737
http://dx.doi.org/10.1016/j.vaccine.2008.03.076
_version_ 1783514086200311808
author Gregersen, Jens-Peter
author_facet Gregersen, Jens-Peter
author_sort Gregersen, Jens-Peter
collection PubMed
description Influenza vaccine production has traditionally relied on the use of embryonated chicken eggs for virus isolation and propagation, but recently, cell-culture-derived manufacturing methods have been introduced. During influenza vaccine production, by either conventional or cell culture methods, there is a risk of incidental contamination by adventitious agents. Thus, a risk-assessment model has been developed to qualitatively assess the potential risk of vaccine process contamination by viral pathogens. The model takes into account the basic growth characteristics of each virus, its ability to grow in different cell substrates and resistance to processing steps during vaccine manufacture. The risk-assessment model has been applied to various pathogens to determine potential risk and relevance in different manufacturing scenarios, using different cell substrates for virus propagation, including Madin–Darby canine kidney (MDCK) cells. Avian viruses, introduced via use of embryonated eggs for virus isolation, were found to present the greatest risk, irrespective of the substrate used for influenza virus propagation. The use of MDCK cells to propagate vaccine virus from egg-isolated influenza virus strains does not introduce a new or greater adventitious virus risk, compared with egg-based vaccine production. Indeed, the adventitious virus risk is potentially reduced as fewer viruses are able to grow in MDCK cells.
format Online
Article
Text
id pubmed-7115387
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71153872020-04-02 A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines Gregersen, Jens-Peter Vaccine Article Influenza vaccine production has traditionally relied on the use of embryonated chicken eggs for virus isolation and propagation, but recently, cell-culture-derived manufacturing methods have been introduced. During influenza vaccine production, by either conventional or cell culture methods, there is a risk of incidental contamination by adventitious agents. Thus, a risk-assessment model has been developed to qualitatively assess the potential risk of vaccine process contamination by viral pathogens. The model takes into account the basic growth characteristics of each virus, its ability to grow in different cell substrates and resistance to processing steps during vaccine manufacture. The risk-assessment model has been applied to various pathogens to determine potential risk and relevance in different manufacturing scenarios, using different cell substrates for virus propagation, including Madin–Darby canine kidney (MDCK) cells. Avian viruses, introduced via use of embryonated eggs for virus isolation, were found to present the greatest risk, irrespective of the substrate used for influenza virus propagation. The use of MDCK cells to propagate vaccine virus from egg-isolated influenza virus strains does not introduce a new or greater adventitious virus risk, compared with egg-based vaccine production. Indeed, the adventitious virus risk is potentially reduced as fewer viruses are able to grow in MDCK cells. Elsevier Ltd. 2008-06-19 2008-04-15 /pmc/articles/PMC7115387/ /pubmed/18468737 http://dx.doi.org/10.1016/j.vaccine.2008.03.076 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Gregersen, Jens-Peter
A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title_full A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title_fullStr A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title_full_unstemmed A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title_short A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
title_sort risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115387/
https://www.ncbi.nlm.nih.gov/pubmed/18468737
http://dx.doi.org/10.1016/j.vaccine.2008.03.076
work_keys_str_mv AT gregersenjenspeter ariskassessmentmodeltoratetheoccurrenceandrelevanceofadventitiousagentsintheproductionofinfluenzavaccines
AT gregersenjenspeter riskassessmentmodeltoratetheoccurrenceandrelevanceofadventitiousagentsintheproductionofinfluenzavaccines